Evidence map›Paper›PMID 40746565›Full record

ReviewFrontiers in immunology2025

Defining criteria for broadly neutralizing HIV antibodies.

Elizabeth-Sharon David-Fung, Katherine A Belobrajdic, Jennifer P Macke, Corey R Quackenbush, Kumkum Ganguly, Jennifer L Mamrosh

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Elizabeth-Sharon David-FungTheoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM, United States.
Katherine A BelobrajdicTheoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM, United States.
Jennifer P MackeTheoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM, United States.
Corey R QuackenbushTheoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM, United States.
Kumkum GangulyTheoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM, United States.
Jennifer L MamroshTheoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over the course of a few years, a small percentage of individuals with HIV-1 develop broadly neutralizing antibodies (bnAbs) capable of neutralizing diverse viruses. Although hundreds of antibodies with neutralizing activity against heterologous viruses have been referred to as bnAbs, there is no universally accepted numerical definition of a bnAb. Here, we will review important elements of HIV neutralizing antibodies and proposed definitions of bnAbs, as well as introduce a web-based tool, CAByN (Choose Antibodies by Neutralization), allowing users to identify antibodies meeting their numerical definitions of a bnAb from data in the Los Alamos HIV Databases CATNAP (Compile, Analyze and Tally NAb Panels) antibody neutralization database. Biological findings from use of CAByN are also presented here, including differential neutralizing activity for certain antibodies across viral clades, and identification of antibodies with suspected incomplete neutralization. Website address: http://hiv.lanl.gov/content/sequence/CABYN/CABYN.html.

Indexed as

Antibodies, NeutralizingHIV-1HIV AntibodiesHIV InfectionsHumansNeutralization TestsAntibodies, NeutralizingHIV Antibodiesantibody breadthBNABbroadly neutralizing antibodiesHIVpotency

Identifiers

PMID40746565
PMCPMC12310620

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.